Grufity logoGrufity logo

EXAS

41.50USD-1.15(-2.70%)Market Closed

Exact Sciences Corp

Market Summary

USD41.50-1.15Market Closed
-2.70%

EXAS Stock Price

RSI Chart

Valuation

Market Cap

6.1B

Price/Earnings

-8.33

Price/Sales

3.16

Price/Cashflow

-20.4

MarketCap/EBT

-8.2

Price/Sales

Profitability

Operating Margin

73.48%

EBT Margin

-38.51%

Return on Equity

-22.89%

Return on Assets

-11.41%

Fundamentals

Revenue

Revenue (TTM)

1.9B

Earnings

Earnings (TTM)

-734.5M

Price Action

52 Week Range

29.2789.99
(Low)(High)

Last 7 days

-2.0%

Last 30 days

20.0%

Last 90 days

16.6%

Trailing 12 Months

-51.4%

Financial Health

Current Ratio

2.48

Debt/Equity

0.01

Debt/Cashflow

-4.3

Investor Care

Peers (Alternatives to Exact Sciences)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
99.4B
27.5B
7.49% 27.03%
24.02
3.61
3.29% -19.86%
59.1B
23.0B
16.17% -46.79%
4.2
2.57
227.55% 302.16%
16.6B
3.3B
4.33% 13.82%
17.56
5
22.05% 179.89%
MID-CAP
6.1B
1.9B
20.01% -51.44%
-8.33
3.16
13.25% 11.39%
5.4B
1.6B
0.96% -1.58%
19.63
3.44
34.45% 189.89%
5.2B
5.4B
-33.77% -66.00%
18.72
0.96
14.55% 17.88%
3.8B
249.9M
-21.94% -61.12%
-24.67
15.19
132.20% -22.25%
3.7B
112.4M
-2.67% -35.96%
-12.87
32.5
-41.50% -607.58%
SMALL-CAP
1.8B
1.3B
-27.72% -92.37%
-1.22
1.39
9.22% -55.36%
955.6M
3.3M
-25.77% -53.21%
-21.05
291.16
-34.21% -41.21%
728.9M
55.0M
-24.07% -79.29%
-1.39
13.26
7.76% -63.87%
335.1M
80.7M
9.94% -54.15%
-3.66
4.15
13.30% 15.53%
19.1M
-
- -66.05%
-2.32
-
- 2.60%
3.4M
-
13.51% -87.93%
-0.06
155.91
- -40.55%

Financials for Exact Sciences

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Revenue4.7%1,9381,8521,7671,7601,712
Cost Of Revenue6.3%514483459439419
  S&GA Expenses2.3%929908862744684
  R&D Expenses0.0%372372386744700
Earnings Before Taxes0.7%-746.42-751.49-842.51-1,027.88-1,081.48
Net Income1.5%-734.55-745.40-595.62-793.35-828.95
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Assets-0.8%6,4376,4916,6856,6546,724
  Current Assets-9.3%1,1021,2151,4261,6161,669
    Cash Equivalents12.5%213190315274364
  Inventory2.0%1151131059590
  Net PPE7.3%623580524502-
  Goodwill0.5%2,3462,3352,3352,2432,243
Liabilities-0.1%3,2283,2323,2973,1973,165
  Current Liabilities-7.8%443481517710676
Shareholder's Equity-1.5%3,2093,2583,3883,4583,559
  Retained Earnings-5.9%-2,988.52-2,822.46-2,641.52-2,420.91-2,253.97
  Additional Paid-In Capital2.0%6,2056,0866,0295,8775,811
Accumulated Depreciation10.4%237215195174-
Shares Outstanding0.7%177176174172172
Float-21,212----
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Cashflow From Operations-50.9%-300.02-198.76-102.2434156
  Share Based Compensation1.1%231228253239217
Cashflow From Investing113.4%96-719.01-1,082.08-1,467.16-1,401.09
Cashflow From Financing1263.8%5448901905

Risks

What is the probability of a big loss on EXAS?

98.5%


Probability that Exact Sciences stock will be more than 20% underwater in next one year

73.5%


Probability that Exact Sciences stock will be more than 30% underwater in next one year.

45.4%


Probability that Exact Sciences stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does EXAS drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Exact Sciences was unfortunately bought at previous high price.

Returns

Cumulative Returns on EXAS

15.5%


10-Year Cumulative Returns

24.2%


7-Year Cumulative Returns

-6.4%


5-Year Cumulative Returns

-20.0%


3-Year Cumulative Returns

What are the long-term rolling returns for EXAS?

FIve years rolling returns for Exact Sciences.

Which funds bought or sold EXAS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-23
Toroso Investments, LLC
SOLD OFF
-100
-68,000
-
-%
2022-11-22
IHT Wealth Management, LLC
ADDED
8.5
-26,000
224,000
0.02%
2022-11-22
Capital Impact Advisors, LLC
ADDED
92.59
90,000
201,000
0.20%
2022-11-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
NEW
-
1,246,000
1,246,000
0.01%
2022-11-21
FourThought Financial, LLC
ADDED
97.53
30,000
78,000
0.01%
2022-11-21
Parallax Volatility Advisers, L.P.
ADDED
32.37
60,000
708,000
-%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
REDUCED
-0.37
-2,035,000
9,383,000
0.02%
2022-11-18
Legend Financial Advisors, Inc.
NEW
-
8,292
8,292
0.01%
2022-11-17
Grandeur Peak Global Advisors, LLC
REDUCED
-40.26
-1,967,000
1,911,000
0.12%
2022-11-17
M&T Bank Corp
SOLD OFF
-100
-244,000
-
-%

1–10 of 36

Latest Funds Activity

Are funds buying EXAS calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own EXAS

Exact Sciences News

Investor's Business Daily

Cathie Wood Has Bet Big On These 10 Stocks.15 hours ago

Yahoo Finance

EXAS Fair Value

Recent SEC filings of Exact Sciences

View All Filings
Date Filed Form Type Document
Nov 03, 2022
8-K
Current Report
Nov 03, 2022
10-Q
Quarterly Report
Oct 13, 2022
4
Insider Trading
Sep 12, 2022
SC 13G/A
Major Ownership Report

Latest Insider Trading transactions for EXAS

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-10-12
Cunningham Everett
SOLD
-529,275
31.37
-16,872
Chief Commercial Officer
2022-10-11
Cunningham Everett
ACQUIRED
-
-
35,006
Chief Commercial Officer
2022-08-05
Baranick Brian
SOLD
-46,366.1
47.12
-984
Gen. Mgr., Precision Oncology
2022-08-04
Baranick Brian
ACQUIRED
-
-
2,712
Gen. Mgr., Precision Oncology
2022-07-26
Zanotti Katherine S
ACQUIRED
46,909.4
10.18
4,608
-
2022-07-26
Zanotti Katherine S
SOLD
-208,005
45.14
-4,608
-
2022-07-01
Conroy Kevin T
SOLD
-285.25
40.75
-7
President and CEO
2022-06-30
Zanotti Katherine S
SOLD
-43,581.2
40.13
-1,086
-
2022-06-09
Clancy Paul J
ACQUIRED
-
-
5,606
-
2022-06-09
Petrovic Shacey
ACQUIRED
-
-
5,606
-

1–10 of 50

Kevin T. Conroy
6500
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

EXAS Income Statement

2022-09-30
Condensed Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]    
Revenue$ 523,073$ 456,379$ 1,531,284$ 1,293,275
Operating expenses    
Cost of sales (exclusive of amortization of acquired intangible assets)147,937115,738427,242339,699
Research and development90,81375,356299,144297,158
Sales and marketing187,697196,617635,800577,585
General and administrative191,968186,541543,410621,897
Amortization of acquired intangible assets23,52623,94074,53670,954
Impairment of long-lived assets5,94620,21012,53720,210
Total operating expenses647,887618,4021,992,6691,927,503
Other operating loss(13,244)0(13,244)0
Loss from operations(138,058)(162,023)(474,629)(634,228)
Other income (expense)    
Investment income (loss), net(8,584)(4,093)(13,790)30,524
Interest expense(5,235)(4,680)(14,224)(13,948)
Total other income (expense)(13,819)(8,773)(28,014)16,576
Net loss before tax(151,877)(170,796)(502,643)(617,652)
Income tax benefit3,1163,8586,882242,638
Net loss$ (148,761)$ (166,938)$ (495,761)$ (375,014)
Net loss per share—basic (in usd per share)$ (0.84)$ (0.97)$ (2.82)$ (2.19)
Net loss per share—diluted (in usd per share)$ (0.84)$ (0.97)$ (2.82)$ (2.19)
Weighted average common shares outstanding—basic (in shares)176,997171,978175,935170,978
Weighted average common shares outstanding—diluted (in shares)176,997171,978175,935170,978

EXAS Balance Sheet

2022-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current Assets:  
Cash and cash equivalents$ 235,306$ 315,471
Marketable securities433,808715,005
Accounts receivable, net189,206216,645
Inventory114,699104,994
Prepaid expenses and other current assets75,48774,122
Total current assets1,048,5061,426,237
Long-term Assets:  
Property, plant and equipment, net670,506580,248
Operating lease right-of-use assets175,945174,225
Goodwill2,345,1802,335,172
Intangible assets, net1,977,6902,094,411
Other long-term assets, net88,73974,591
Total assets6,306,5666,684,884
Current Liabilities:  
Accounts payable63,58367,829
Accrued liabilities307,990398,556
Operating lease liabilities, current portion27,05419,710
Other current liabilities25,04930,973
Total current liabilities423,676517,068
Long-term Liabilities:  
Convertible notes, net2,184,6252,180,232
Long-term debt50,0000
Other long-term liabilities354,998417,782
Operating lease liabilities, less current portion184,633182,166
Total liabilities3,197,9323,297,248
Commitments and contingencies (Note 14)
Stockholders’ Equity:  
Preferred stock, $0.01 par value Authorized—5,000,000 shares issued and outstanding—no shares at September 30, 2022 and December 31, 202100
Common stock, $0.01 par value Authorized—400,000,000 shares issued and outstanding—177,253,533 and 173,674,067 shares at September 30, 2022 and December 31, 20211,7741,738
Additional paid-in capital6,255,2116,028,861
Accumulated other comprehensive loss(11,070)(1,443)
Accumulated deficit(3,137,281)(2,641,520)
Total stockholders’ equity3,108,6343,387,636
Total liabilities and stockholders’ equity$ 6,306,566$ 6,684,884